Inactive Instrument

News Sigyn Therapeutics, Inc. Other OTC

Equities

SIGY

US82674U1060

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Sigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth Conference	05/03	AQ
Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K	21/02	AQ
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/02	CI
Sigyn Therapeutics Announces Reverse Stock Split	30/01	AQ
Sigyn Therapeutics Releases Letter to Shareholders	04/01	AQ
Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer	12/12	CI
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer	12/12	AQ
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results	15/11	AQ
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity	04/23/04	AQ
Sigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference	06/23/06	AQ
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results	15/23/15	AQ
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Sigyn Therapeutics to Present at Tomorrow’s Emerging Growth Conference	08/23/08	AQ
Sigyn Therapeutics to Present at the OTCQB Venture Virtual Investor Conference on August 3rd	31/23/31	AQ
Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application	17/23/17	AQ
Sigyn Therapeutics, Inc. Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep Trademark Application	17/23/17	CI
Sigyn Therapeutics Reports First Quarter 2023 Financial Results	16/23/16	AQ
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
SIGYN THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	14/23/14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sigyn Therapeutics, Inc. Other OTC

Equities

SIGY

US82674U1060

Summary

Filters